These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 16859425)
1. Pharmacogenetics of chronic cardiovascular drugs: applications and implications. Zineh I; Johnson JA Expert Opin Pharmacother; 2006 Aug; 7(11):1417-27. PubMed ID: 16859425 [TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009. Joseph PG; Pare G; Ross S; Roberts R; Anand SS Clin Cardiol; 2014 Jan; 37(1):48-56. PubMed ID: 24105892 [TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management. Humma LM; Terra SG Am J Health Syst Pharm; 2002 Jul; 59(13):1241-52. PubMed ID: 12116890 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine. Nakagawa K; Ishizaki T Pharmacol Ther; 2000 Apr; 86(1):1-28. PubMed ID: 10760544 [TBL] [Abstract][Full Text] [Related]
6. A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application? Verschuren JJ; Trompet S; Wessels JA; Guchelaar HJ; de Maat MP; Simoons ML; Jukema JW Eur Heart J; 2012 Jan; 33(2):165-75. PubMed ID: 21804109 [TBL] [Abstract][Full Text] [Related]
7. Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. Friede K; Li J; Voora D Clin Chem; 2017 Jan; 63(1):177-185. PubMed ID: 27864383 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice. Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics in Cardiovascular Medicine. Weeke PE Adv Pharmacol; 2018; 83():333-360. PubMed ID: 29801582 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular drug therapy in the elderly. Aronow WS; Frishman WH; Cheng-Lai A Cardiol Rev; 2007; 15(4):195-215. PubMed ID: 17575484 [TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of beta-blockers. Shin J; Johnson JA Pharmacotherapy; 2007 Jun; 27(6):874-87. PubMed ID: 17542770 [TBL] [Abstract][Full Text] [Related]
15. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues. Borghi C; ; Rossi F; High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596 [TBL] [Abstract][Full Text] [Related]
16. The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Cresci S Expert Opin Pharmacother; 2005 Dec; 6(15):2577-91. PubMed ID: 16316298 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular drug therapy in the elderly: theoretical and practical considerations. Williams BR; Kim J Drugs Aging; 2003; 20(6):445-63. PubMed ID: 12710864 [TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic implications of the eNOS polymorphisms for cardiovascular action drugs. Silva PS; Lacchini R; Gomes Vde A; Tanus-Santos JE Arq Bras Cardiol; 2011 Feb; 96(2):e27-34. PubMed ID: 21445464 [TBL] [Abstract][Full Text] [Related]
20. Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases. Zaiou M; Benachour H; Marteau JB; Visvikis-Siest S; Siest G Curr Pharm Des; 2009; 15(27):3193-206. PubMed ID: 19754391 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]